Rilpivirine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Rilpivirine" ([Edit=Allow only autoconfirmed users] (expires 14:49, 16 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:49, 16 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{Drugbox
__NOTOC__
| IUPAC_name        = 4-{[4-({4-[(''E'')-2-cyanoethenyl]-2,6-dimethylphenyl}<br>amino)pyrimidin-2-yl]amino}benzonitrile
{{Rilpivirine}}
| image            = Rilpivirine.svg
{{CMG}}; {{AE}} {{chetan}}
| CAS_number        = 500287-72-9
 
| ATC_prefix        =
==Overview==
| ATC_suffix        =
| PubChem          = 6451164
| DrugBank          =
| C=22|H=18|N=6
| molecular_weight  = 366.42 g/mol
| bioavailability  =
| protein_bound    =
| metabolism        =
| elimination_half-life = 38 hours
| excretion        =
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      =
| routes_of_administration = Oral
}}
'''Rilpivirine''' (TMC278) is a [[diarylpyrimidine]] under under investigation as a treatment for [[HIV]] infection.  It is a [[non-nucleoside reverse transcriptase inhibitor]] with many times the potency of current available agents in that class, such as [[efavirenz]].<ref>{{cite journal |author=Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B |title=Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects |journal=AIDS |volume=20 |issue=13 |pages=1721–6 |year=2006 |pmid=16931936 |doi=10.1097/01.aids.0000242818.65215.bd |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00002030-200608220-00005}}</ref><ref>Pozniak A, Morales-Ramirez J, Mohap L et al. [http://www.retroconference.org/2007/Abstracts/30659.htm 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients.] Oral abstract 144LB.
'''Rilpivirine''' (TMC278) is a [[diarylpyrimidine]] under under investigation as a treatment for [[HIV]] infection.  It is a [[non-nucleoside reverse transcriptase inhibitor]] with many times the potency of current available agents in that class, such as [[efavirenz]].<ref>{{cite journal |author=Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B |title=Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects |journal=AIDS |volume=20 |issue=13 |pages=1721–6 |year=2006 |pmid=16931936 |doi=10.1097/01.aids.0000242818.65215.bd |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00002030-200608220-00005}}</ref><ref>Pozniak A, Morales-Ramirez J, Mohap L et al. [http://www.retroconference.org/2007/Abstracts/30659.htm 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients.] Oral abstract 144LB.
</ref>It is expected to be [[FDA]] approved as soon as 2009.<ref>Steve Mitchell. [http://www.terradaily.com/reports/HIV_Market_To_Top_10_Billion_Dollars_999.html HIV Market To Top 10 Billion Dollars]. United Press International. April 11, 2007.</ref>
</ref>It is expected to be [[FDA]] approved as soon as 2009.<ref>Steve Mitchell. [http://www.terradaily.com/reports/HIV_Market_To_Top_10_Billion_Dollars_999.html HIV Market To Top 10 Billion Dollars]. United Press International. April 11, 2007.</ref>


==Category==
Antiretroviral
==US Brand Names==
Edurant
==FDA Package Insert==


'''  [[Rilpivirine description|Description]]'''
'''| [[Rilpivirine clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Rilpivirine microbiology|Microbiology]]'''
'''| [[Rilpivirine indications and usage|Indications and Usage]]'''
'''| [[Rilpivirine contraindications|Contraindications]]'''
'''| [[Rilpivirine warnings and precautions|Warnings and Precautions]]'''
'''| [[Rilpivirine adverse reactions|Adverse Reactions]]'''
'''| [[Rilpivirine drug interactions|Drug Interactions]]'''
'''| [[Rilpivirine overdosage|Overdosage]]'''
'''| [[Rilpivirine clinical studies|Clinical Studies]]'''
'''| [[Rilpivirine dosage and administration|Dosage and Administration]]'''
'''| [[Rilpivirine how supplied|How Supplied]]'''
'''| [[Rilpivirine labels and packages|Labels and Packages]]'''
==Mechanism of Action==
A HIV-1 replication inhibitor acting by non-competitive inhibition of HIV-1 reverse transcriptase .  It is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1)
==References==
==References==
{{reflist|2}}
{{Reflist|2}}
 
{{HIVpharm}}


{{pharm-stub}}
[[Category:Antibiotics]]
[[Category:Non-nucleoside reverse transcriptase inhibitors]]
[[Category:Wikinfect]]

Revision as of 00:17, 10 January 2014

Rilpivirine
EDURANT® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

Rilpivirine (TMC278) is a diarylpyrimidine under under investigation as a treatment for HIV infection. It is a non-nucleoside reverse transcriptase inhibitor with many times the potency of current available agents in that class, such as efavirenz.[1][2]It is expected to be FDA approved as soon as 2009.[3]

Category

Antiretroviral

US Brand Names

Edurant

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

A HIV-1 replication inhibitor acting by non-competitive inhibition of HIV-1 reverse transcriptase . It is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1)

References

  1. ↑ Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B (2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS. 20 (13): 1721–6. doi:10.1097/01.aids.0000242818.65215.bd. PMID 16931936.
  2. ↑ Pozniak A, Morales-Ramirez J, Mohap L et al. 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB.
  3. ↑ Steve Mitchell. HIV Market To Top 10 Billion Dollars. United Press International. April 11, 2007.
Retrieved from "https://www.wikidoc.org/index.php?title=Rilpivirine&oldid=931106"